MARKETS
Markets

Niki BioSolutions' DiamiR Biosciences Subsidiary To Perform Apolipoprotein E Genotyping On Plasma Samples From Global Alzheimer’s Platform Foundation Bio-Hermes-002 Trial Group

Oct 14, 2026 · 08:03 AM ET· updated 1h ago

Niki BioSolutions, Inc. (NASDAQ: NIKI) ("Niki" or the "Company"), a clinical-stage life sciences company focused on unmet medical needs and genomic and biomarker testing solutions, today announced that

Share
Why It Matters

Niki's lab unit will run genetic tests on Alzheimer's study samples. This shows the company is working on real medical projects that matter.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.